PamGene
PamGene, operating as PamDx, is a Netherlands-based biotechnology company that provides multiplex, functional kinase activity profiling services to pharmaceutical and biotechnology firms, diagnostic laboratories, and scientific researchers for drug development, immuno-oncology patient stratification, and disease mechanism research.
- Company typePrivate
- Founded2000
- Headquarters's-hertogenbosch, Netherlands
- Headcount11–50
- GTM typeB2B
- OfferingServices
What PamGene does
PamGene, commercially operating as PamDx, is a Netherlands-based molecular diagnostics and biotechnology company founded in 2000 and headquartered in 's-Hertogenbosch. The company specializes in multiplex, functional kinase activity profiling technology that measures kinase activity across cellular signaling networks, enabling kinome-based biomarker analysis. This technology is positioned to support drug discovery, mechanism-of-action studies, patient stratification in immuno-oncology, and broader disease mechanism research.
The company's commercial offering is built around the PamDx platform, organized into three service modules: Diagnostics (immuno-oncology patient stratification and personalized therapy selection), Pharma & Biotech (discovery, optimization, and mechanistic analysis of therapeutic kinase inhibitor candidates), and Science (kinome and mechanistic insights for biological models used in academic and translational research). Its proprietary functional kinase activity profiling method is described as a novel multiplex architecture that reveals cellular signaling patterns beyond what traditional biomarker approaches capture.
PamGene/PamDx operates a B2B, sales-led professional services model with a quote-based engagement structure typical of specialty diagnostics and CRO services. It targets enterprise pharmaceutical and biotechnology customers developing kinase inhibitors, diagnostic laboratories supporting immuno-oncology treatment decisions, and scientific research institutions. The company is privately held with disclosed institutional funding history from Alta Partners, Gimv, EQT Life Sciences, and LCF Rothschild, plus a 2023 Eurostars grant; total disclosed funding is approximately $21.3M over the company's history. Its only confirmed operating geography is Europe, with no disclosed North American or Asian commercial presence.
PamGene firmographics
Firmographics- Name
- PamGene
- Legal name
- PamGene
- Website
- https://pamgene.com
- Company type
- Private
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- PamGene, operating as PamDx, is a Netherlands-based biotechnology company that provides multiplex, functional kinase activity profiling services to pharmaceutical and biotechnology firms, diagnostic laboratories, and scientific researchers for drug development, immuno-oncology patient stratification, and disease mechanism research.
- Ownership category
- akta.pro rank
PamGene industry classification
Industry- Product category
- Molecular Diagnostics Services
- NAICS
- Research and Development in the Physical, Engineering, and Life Sciences (54171)
- akta.pro primary industry
- DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms (HLACANAM)
Keywords
Where PamGene is headquartered
LocationHeadquarters
- HQ city
- 's-hertogenbosch
- HQ country
- Netherlands
- HQ region
- Europe
Offices1 record
Markets served
PamGene business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Kinase Activity Profiling Services: B2B service model providing multiplex functional kinase activity profiling to pharmaceutical companies, biotech firms, and diagnostic laboratories for drug development optimization, patient stratification, and biological research
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
PamGene product offering
Product offeringCore offering
PamGene provides multiplex, functional kinase activity profiling services through its PamDx technology platform, generating kinome-based biomarker data and mechanistic insights into cellular signaling. Services are organized into three application areas: Diagnostics (immuno-oncology patient stratification), Pharma & Biotech (therapeutic kinase inhibitor discovery and optimization), and Science (kinome profiling for biological models). The offering is delivered as a B2B service to pharmaceutical companies, biotechnology firms, and diagnostic laboratories.
Product overview
PamDx is a unified technology platform and service offering built around multiplex, functional kinase activity profiling. The core platform enables kinome-based biomarker analysis and mechanistic insights into cellular signaling for disease understanding and therapy optimization. The portfolio consists of three interconnected service modules: Diagnostics (patient stratification for Immuno Oncology), Pharma & Biotech (therapeutic kinase inhibitor discovery and optimization), and Science (biological model analysis). The platform is designed to guide drug development and personalized therapy selection.
Differentiator
Problem solved
Functional benefit
Products and services
- PamDx Platform A multiplex, functional kinase activity profiling technology platform that reveals the broader picture of cellular signaling and provides mechanistic insights needed to fully understand diseases and cell alterations. Used for guiding drug development and personalized therapy selection with kinome-based biomarkers.
- Diagnostics Service Module Expertise in immuno-oncology treatment and development optimization through patient stratification, supporting physicians in finding solutions to improve and optimize patient treatment.
- Pharma & Biotech Service Module Discovery, optimization, and analysis of therapeutic kinase inhibitor candidates for pharmaceutical and biotechnology companies, including mechanism-of-action studies.
- Science Service Module Provides 'Kinome' and mechanistic insights for biological models, supporting scientific research and understanding of diseases.
Companies that use PamGene
Customer profileSegments3 records
Ideal customer profiles3 records
PamGene technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
PamGene partnerships and signals
Strategic signalExpansion highlights4 records
PamGene competitors and assessment
Company assessmentPeers
Direct peers
- Reaction Biology: Reaction Biology provides kinase profiling services and assay products to pharma and biotech customers. Directly comparable as a fee-for-service kinase activity profiling CRO serving similar drug-discovery use cases.
Broad incumbents
- Eurofins Scientific: Global CRO offering broad bioanalytical and pharma services including kinase and biomarker testing. Comparable as an established incumbent that can offer kinase profiling at greater scale, often bundling with larger programs.
- Charles River Laboratories: Large CRO with integrated discovery and safety assessment services including kinase and cell-based assay work. Comparable as a broader incumbent offering competing profiling capabilities within a full-service CRO model.
- Thermo Fisher Scientific: Life sciences tools and services leader with phosphoproteomics and kinase assay capabilities via its proteomics and bioscience divisions. Comparable as a large incumbent whose scale and instrument ecosystems could compete with niche profiling services.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights5 records
Customer concentration
PamGene social profiles
Digital presencePamGene financial estimates
Financial estimateRevenue estimate
Valuation estimate
PamGene leadership team
Management profileNumber of profiles
Profiles2 records
PamGene funding detail
Funding detailFunding overview
Funding rounds4 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PamGene M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PamGene
What does PamGene do?
PamGene provides multiplex, functional kinase activity profiling services through its PamDx technology platform, generating kinome-based biomarker data and mechanistic insights into cellular signaling. Services are organized into three application areas: Diagnostics (immuno-oncology patient stratification), Pharma & Biotech (therapeutic kinase inhibitor discovery and optimization), and Science (kinome profiling for biological models). The offering is delivered as a B2B service to pharmaceutical companies, biotechnology firms, and diagnostic laboratories.
Is PamGene a public or private company?
PamGene is a private company. It is classified as venture growth investor backed and is currently operating.
When was PamGene founded?
PamGene was founded in 2000. It employs 11 to 50 people.
Where is PamGene based?
PamGene is headquartered in 's-hertogenbosch, Netherlands, in the Europe region.
How does PamGene make money?
One revenue line is on record: kinase Activity Profiling Services.
Who are PamGene's main competitors?
Cell Signaling Technology is listed as a peer. Reaction Biology is listed as a direct peer. Broad incumbents are Eurofins Scientific, Charles River Laboratories and Thermo Fisher Scientific.
Does PamGene have an API?
No public API is recorded for PamGene.
What industry is PamGene in?
PamGene's product category is Molecular Diagnostics Services. Its primary akta.pro industry code is HLACANAM, DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms. Its NAICS code is 54171.